Prostate cancer vaccine (GVAX) is an allogeneic vaccination strategy in which prostate cancer cells are genetically engineered to secrete high levels of GM-CSF, then mixed with autologous patient mononuclear cells ex vivo and reinfused. This evidence concerns the gene CSF2 and prostate cancer.